On February 5, 2026, the FDA approved VYBRIQUE, the first and only oral film formulation of sildenafil for treating erectile dysfunction in men aged 18 and older. Developed by IBSA USA, the single-dose film dissolves on the tongue without water, providing a discreet, on-the-go alternative to traditional pills that can be taken 30 minutes to 4 hours before sexual activity. The product became commercially available for direct home delivery nationwide in March 2026.
Why It Matters
VYBRIQUE represents the first genuinely new delivery format for ED medication in years, and its DTC fulfillment model signals further disintermediation of traditional pharmacy channels. For the broader male sexual health market, the approval validates that the FDA sees room for innovation beyond generic pills — which could encourage other companies to pursue novel delivery mechanisms for sexual health medications.VYBRIQUE was evaluated in a randomized, double-blind, placebo-controlled study of 475 adult men with ED across four dosage strengths: 25 mg, 50 mg, 75 mg, and 100 mg. Over the 12-week study, the film demonstrated superior improvements in sexual function compared to placebo across the co-primary efficacy endpoints assessed at Week 4. The dissolvable film format eliminates the need for water, discreet packaging, and the social awkwardness of pulling out a pill bottle.
IBSA, the Swiss pharmaceutical company behind VYBRIQUE, has significant experience with oral film drug delivery technology and sees the ED market as a prime application for the format. The company is offering direct home delivery across all 50 states, bypassing traditional pharmacy channels in a move that mirrors the DTC telehealth model pioneered by Hims and Ro.
The approval comes as the ED treatment market continues to evolve beyond the traditional pill format. With generic sildenafil and tadalafil widely available through telehealth platforms, VYBRIQUE is competing not on the active ingredient but on the delivery mechanism — betting that convenience, discretion, and the "cool factor" of a dissolving film will command a premium.
Sources
- IBSA USA Announces FDA Approval of VYBRIQUE — BusinessWire
- FDA Approves Sildenafil as First Oral Film for ED — Drug Topics
- FDA Approves VYBRIQUE — BioSpace
Update — 2026-03-15
Initial entry — story first created.